<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923557</url>
  </required_header>
  <id_info>
    <org_study_id>IUPU-16-UTUC-2</org_study_id>
    <nct_id>NCT02923557</nct_id>
  </id_info>
  <brief_title>Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <brief_summary>
    <textblock>
      This clinical trial is designed to evaluate the efficacy of single immediate intravesical&#xD;
      chemotherapy instillation in the prevention of bladder recurrence after nephroureterectomy&#xD;
      for primary upper tract urothelial carcinoma (UTUC) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INTRODUCTION&#xD;
&#xD;
      Upper tract urothelial carcinomas (UTUC) are relatively uncommon compared to bladder cancer&#xD;
      and account for only 5-10% of urothelial carcinomas, with an estimated annual incidence in&#xD;
      Western countries of ~2 cases per 100,000 inhabitants. In 17% of cases, concurrent bladder&#xD;
      cancer is present. Recurrence in the bladder after management of UTUC occurs in 22-47% of&#xD;
      UTUC patients, compared with 2-6% in the contralateral upper tract. At our institution, we&#xD;
      reported that 30.8% of UTUC patients developed intravesical recurrence, which was in line&#xD;
      with the global trend.&#xD;
&#xD;
      Generally speaking, the field cancerization hypothesis and intraluminal seeding are currently&#xD;
      the two main concepts to explain multifocality of urothelial cancer and the recurrent bladder&#xD;
      tumor. Independent multiclonal tumor development after carcinogenic exposure of the entire&#xD;
      urothelial and intraluminal implantation followed by clonally induced single progenitor cell&#xD;
      evolution are the mechanisms suggested. While the two mechanisms could co-exist, the&#xD;
      intraluminal seeding hypothesis is becoming more prevalent with the emergence of more&#xD;
      evidence from molecular studies. Thus postoperative intravesical chemotherapy could&#xD;
      potentially remove the implantation cell and prevent recurrence. While intravesical&#xD;
      instillation is widely used to prevent recurrence after transurethral resection for primary&#xD;
      bladder tumors, there is still no consensus on the prophylactic capability of intravesical&#xD;
      chemotherapy in preventing bladder recurrence after nephroureterctomy for UTUC. According to&#xD;
      a previous prospective, multicentre, randomised clinical trial, a single postoperative dose&#xD;
      of intravesical mitomycin C appears to reduce the risk of a bladder tumour within the first&#xD;
      year following nephroureterectomy for UTUCs.&#xD;
&#xD;
      AIM OF THE WORK This clinical trial is designed to evaluate the efficacy of single immediate&#xD;
      intravesical chemotherapy instillation in the prevention of bladder recurrence after&#xD;
      nephroureterectomy for UTUCs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intravesical recurrence-free survival</measure>
    <time_frame>three years after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cancer-specific survival</measure>
    <time_frame>three years after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bladder Recurrence</condition>
  <condition>Upper Tract Urothelial Carcinoma</condition>
  <condition>Nephroureterectomy</condition>
  <arm_group>
    <arm_group_label>Blank control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>do not use prophylactic intravesical chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single intravesical instillation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravesical instillation within 24 hours postoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirarubicin</intervention_name>
    <description>single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy.</description>
    <arm_group_label>Single intravesical instillation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suspected UTUC patients without history of bladder tumor.&#xD;
&#xD;
          -  Suspected UTUC patients without synchronous bladder tumor.&#xD;
&#xD;
          -  Suspected UTUC patients without contralateral UTUCs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with history of bladder tumor.&#xD;
&#xD;
          -  Patients with synchronous bladder tumor.&#xD;
&#xD;
          -  Patients with contralateral UTUCs.&#xD;
&#xD;
          -  Patients with advanced stage (T4).&#xD;
&#xD;
          -  Patients with other malignant tumors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xuesong LI, M.D.</last_name>
    <phone>8601083572481</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Frist Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gengyan XIONG</last_name>
    </contact>
    <contact_backup>
      <last_name>Runqi GUO</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>October 1, 2016</study_first_submitted>
  <study_first_submitted_qc>October 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Xuesong Li</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

